RGEN
Price
$123.31
Change
+$2.73 (+2.26%)
Updated
Sep 5, 02:31 PM (EDT)
Capitalization
6.78B
60 days until earnings call
STXS
Price
$2.88
Change
+$0.12 (+4.35%)
Updated
Sep 5, 02:38 PM (EDT)
Capitalization
251.35M
62 days until earnings call
Interact to see
Advertisement

RGEN vs STXS

Header iconRGEN vs STXS Comparison
Open Charts RGEN vs STXSBanner chart's image
Repligen
Price$123.31
Change+$2.73 (+2.26%)
Volume$1.2K
Capitalization6.78B
Stereotaxis
Price$2.88
Change+$0.12 (+4.35%)
Volume$105
Capitalization251.35M
RGEN vs STXS Comparison Chart in %
Loading...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGEN vs. STXS commentary
Sep 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Hold and STXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2025
Stock price -- (RGEN: $120.58 vs. STXS: $2.76)
Brand notoriety: RGEN and STXS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: RGEN: 107% vs. STXS: 49%
Market capitalization -- RGEN: $6.78B vs. STXS: $251.35M
RGEN [@Pharmaceuticals: Other] is valued at $6.78B. STXS’s [@Pharmaceuticals: Other] market capitalization is $251.35M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $162.93B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGEN’s FA Score shows that 1 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • RGEN’s FA Score: 1 green, 4 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, STXS is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGEN’s TA Score shows that 3 TA indicator(s) are bullish while STXS’s TA Score has 4 bullish TA indicator(s).

  • RGEN’s TA Score: 3 bullish, 6 bearish.
  • STXS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, STXS is a better buy in the short-term than RGEN.

Price Growth

RGEN (@Pharmaceuticals: Other) experienced а -1.30% price change this week, while STXS (@Pharmaceuticals: Other) price change was -1.78% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.39%. For the same industry, the average monthly price growth was +7.03%, and the average quarterly price growth was +18.51%.

Reported Earning Dates

RGEN is expected to report earnings on Nov 04, 2025.

STXS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.39% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($6.78B) has a higher market cap than STXS($251M). STXS YTD gains are higher at: 21.053 vs. RGEN (-16.229). RGEN has higher annual earnings (EBITDA): 99.5M vs. STXS (-22.41M). RGEN has more cash in the bank: 709M vs. STXS (6.97M). STXS has less debt than RGEN: STXS (5.73M) vs RGEN (686M). RGEN has higher revenues than STXS: RGEN (674M) vs STXS (31.8M).
RGENSTXSRGEN / STXS
Capitalization6.78B251M2,703%
EBITDA99.5M-22.41M-444%
Gain YTD-16.22921.053-77%
P/E Ratio521.44N/A-
Revenue674M31.8M2,119%
Total Cash709M6.97M10,177%
Total Debt686M5.73M11,978%
FUNDAMENTALS RATINGS
RGEN vs STXS: Fundamental Ratings
RGEN
STXS
OUTLOOK RATING
1..100
5884
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
7941
P/E GROWTH RATING
1..100
260
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGEN's Valuation (95) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.

RGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.

RGEN's SMR Rating (92) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.

STXS's Price Growth Rating (41) in the Medical Specialties industry is somewhat better than the same rating for RGEN (79) in the Biotechnology industry. This means that STXS’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for STXS (60) in the Medical Specialties industry. This means that RGEN’s stock grew somewhat faster than STXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGENSTXS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 16 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KIROY6.150.30
+5.13%
Kumba Iron Ore Ltd.
RHEP1.890.09
+4.89%
Regional Health Properties, Inc.
DNZOF15.07N/A
N/A
Denso Corp.
LTGHF0.79N/A
N/A
Life Healthcare Group Holdings Ltd
MHIVF0.09N/A
N/A
Invesque Inc.

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+3.79%
DHR - RGEN
67%
Closely correlated
-0.21%
A - RGEN
66%
Loosely correlated
+2.60%
BIO - RGEN
63%
Loosely correlated
+0.48%
MTD - RGEN
61%
Loosely correlated
+1.51%
BLFS - RGEN
59%
Loosely correlated
+3.31%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with TWST. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+1.85%
TWST - STXS
37%
Loosely correlated
-1.42%
SMTI - STXS
34%
Loosely correlated
+1.58%
PSNL - STXS
33%
Loosely correlated
+4.95%
VCYT - STXS
33%
Poorly correlated
+2.94%
RGEN - STXS
33%
Poorly correlated
+3.79%
More